Loading...
•
Sep 30, 2021
VYNE Q3 2021 Earnings Report
Announced third quarter 2021 financial results and provided a business update.
Key Takeaways
VYNE Therapeutics reported revenues of $4.1 million for the third quarter ended September 30, 2021, compared to $3.3 million for the three months ended September 30, 2020.
VYNE is fully engaged in the development of next-generation therapeutics designed to address multiple immuno-inflammatory diseases.
Lead BET inhibitor candidate, VYN201, demonstrates potent anti-inflammatory effect in preclinical studies and is expected to enter clinic in 2022.
Phase 2a results for FMX114 in Mild-to-Moderate Atopic Dermatitis are expected early Q1 2022.
Process for sale of topical minocycline franchise continues to advance.
Forward Guidance
VYNE expects to communicate the initial indication it will be pursuing for VYN201 and expects to enter the program into the clinic in 2022. Topline results from the Phase 2a portion of the study are anticipated early in the first quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...